worldpharmaceuticals.net
Cure8 news brief
Lilly secures FDA approval for Omvoh to treat Crohn's disease
Medications
Mirikizumab
IL-23 inhibitor
Abdominal Pain
Urgency
FDA Approval
Adult patients
Patients On Biologics
Why This Matters
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
The approval is based on Phase 3 results showing clinical remission and endoscopic healing at one year, outcomes that matter to people living with IBD.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients with ulcerative colitis interested in IL-23 therapies, clinicians who treat IBD, and researchers following biologic drug development.
Study Snapshot
Story typeCompany update
Evidence typeFDA Approval
Source depthFull source text
What To Know
Omvoh is a biologic that targets the IL-23 pathway and is now approved in the US for two IBD indications (Crohn’s disease and ulcerative colitis). The company-reported Phase 3 data highlighted rates of clinical remission and endoscopic healing at one year and earlier endoscopic improvements at three months versus placebo.
The article lists labeled warnings and common side effects consistent with the drug’s safety profile. Practical points: This is a regulatory approval announcement summarizing sponsor-reported trial outcomes and safety remarks. It does not provide full study datasets, prescribing details, or comparative effectiveness versus other IBD treatments.
Patients should discuss with their clinicians whether Omvoh is an appropriate option and review official prescribing information for warnings and monitoring requirements.
Keep In Mind
This article is an industry news report summarizing Lilly’s announcement and sponsor-reported Phase 3 results. It does not replace full peer-reviewed study publications, regulatory labeling, or clinical guidance. Safety notes and real-world access (insurance, guidelines) will affect how quickly patients may be prescribed this medicine.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationworldpharmaceuticals.net
Indexed viaGoogle News
Source typeCompany update
PublishedJan 16, 2025, 12:48 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults - PMLiVE
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...